The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Detects a band of approximately 36 kDa (predicted molecular weight: 36 kDa).
FunctionMay play an important role in endothelial cell activation. May act as a nuclear transcription factor that negatively regulates the expression of cardiac genes. Induction seems to be correlated with apoptotic cell death in hepatoma cells.
Tissue specificityMainly expressed in activated vascular endothelial cells. To a lower extent, also expressed in hepatoma cells.
Involvement in diseaseDefects in ANKRD1 may be a cause of total anomalous pulmonary venous return (TAPVR) [MIM:106700]. TAPVR is a rare congenital heart disease (CHD) in which the pulmonary veins fail to connect to the left atrium during cardiac development, draining instead into either the right atrium or one of its venous tributaries. This disease accounts for 1.5% of all CHDs and has a prevalence of approximately 1 out of 15'000 live births.
Ankyrin repeat domain containing protein 1 antibody
Ankyrin repeat domain-containing protein 1 antibody
C 193 antibody
Cardiac ankyrin repeat protein antibody
Cytokine inducible nuclear protein antibody
Cytokine-inducible gene C-193 protein antibody
Cytokine-inducible nuclear protein antibody
Liver ankyrin repeat domain 1 antibody
Anti-ANKRD1 antibody images
Western blot - ANKRD1 antibody (ab64963)
All lanes : Anti-ANKRD1 antibody (ab64963) at 1/500 dilution
Lane 1 : COLO205 cell extract Lane 2 : COLO205 cell extract with immunising peptide at 5 µg
Lysates/proteins at 5 µg per lane.
Predicted band size : 36 kDa Observed band size : 36 kDa
References for Anti-ANKRD1 antibody (ab64963)
This product has been referenced in:
Band M et al. The muscle ankyrin repeat proteins are hypoxia-sensitive: in vivo mRNA expression in the hypoxia-tolerant blind subterranean mole rat, Spalax ehrenbergi. J Mol Evol70:1-12 (2010).
Read more (PubMed: 19967343) »